IN THE CLAIMS:

Please amend Claims 1-7 and 13, by replacing them with the following Rewritten Claims. A copy of the Marked-up Claims is attached for the Examiner's convenience.

Rewritten Claims

1. A pharmaceutical composition comprising a compound of Formula I,



(I)

wherein

R^1 is selected from alkyl; aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with a hydroxyloweralkyl; benzimidaz-2-yl;



wherein R^4 is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl; $NHCH_2CH_2OX$ wherein X represents an *in vivo* hydrolyzable ester; and C_2-C_4 alkyl-(R^5)(R^6) wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

R^2 and R^3 are independently selected from H, NO_2, halo, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that both R^2 and R^3 are not both hydrogen.

3. A pharmaceutical composition according to claim 2, wherein R^1 is selected from aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with hydroxyloweralkyl; benzimidaz-2-yl; $NHCH_2CH_2OX$ wherein X represents an *in vivo* hydrolyzable ester; and C_2-C_4 alkyl-(R^5)(R^6) wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

R^2 and R^3 are independently selected from H, NO_2, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that both R^2 and R^3 are not both hydrogen.

4. A pharmaceutical composition according to claim 3, wherein R^1 is selected from amino monosubstituted or disubstituted with hydroxyloweralkyl; $NHCH_2CH_2OX$ wherein X represents an *in vivo* hydrolyzable ester; and C_2-C_4 alkyl-(R^5)(R^6) wherein one of R^5 and R^6 is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

R^2 and R^3 are independently selected from H, loweralkyl and NO_2, with the proviso that both R^2 and R^3 are not both hydrogen.

5. A pharmaceutical composition according to claim 1 wherein the compound of Formula I is selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

2-{2-(4-Methylphenylsulphonamido)phenyl}-6-(N,N-dimethylamino)-naphthalimide;

N-Octyl-5-nitronaphthalimide;

2-{2-(4-Methylbenzsulphonamido)-4,5-dichlorophenyl}naphthalimide;

3-Nitro-1,8-(N-propioncarboxylate)succinamidonapthalene;

3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

2-(Benzimidaz-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

1,3-Dioxo-2-{4,5-dimethyl-2-(4-methylphenylsulphonamido)phenyl}-
1,2,3,4-tetrahydrobenzo[i]isoquinoline;

3-Methyl-3-(1,3-dioxo-5-nitro(1H,3H)benz[de]isoquinolyl)butyric acid methylester;

N-(4-Ethoxyphenyl)-5-nitronaphthalimide;

Ethyl-5-nitro-1,3-dioxo-1H-benz[de]isoquinoline-2-3H-acetate;

Naphthalicacid-N,N'-diimide;

5-Amino-N-butylnaphthalimide;

1,3-Dioxo-5-nitro-n-propylmorpholino-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and

N-(1,3-Dioxo-6-phenylmercapto-1,2,3,4-tetrahydrobenzo[i]isoquinoline)-
aminoethanol.

6. A pharmaceutical composition according to claim 2 wherein the compound of Formula I is selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

N-Octyl-5-nitronaphthalimide;

2-{2-(4-Methylbenzsulphonamido)-4,5-dichlorophenyl}naphthalimide;

3-Nitro-1,8-(N-propioncarboxylate)succinamidonapthalene;

3-Amino-7,4-bis(ethyl-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and

2-(Benzimidaz-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline.

7. A pharmaceutical composition according to claim 1 wherein the compound of Formula I is N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol or its pharmaceutically acceptable salt.

13. An *in vivo* hydrolyzable ester or amide of a compound selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

3-Nitro-1,8-(N-propioncarboxylate)succinamidonapthalene;

3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and

2-(2-Hydroxyphenyl)naphthalimide.

Please cancel claim 8 without prejudice or disclaimer.

Please add new Claims 14-19 as follows:

New Claims

14. A method of treating pain in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a composition as defined in claim 1.

15. A method of treating Alzheimer's disease in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a composition as defined in claim 1.